PMID- 37127633
OWN - NLM
STAT- MEDLINE
DCOM- 20230503
LR  - 20230504
IS  - 1475-2875 (Electronic)
IS  - 1475-2875 (Linking)
VI  - 22
IP  - 1
DP  - 2023 May 2
TI  - Coverage of intermittent preventive treatment of malaria in infants after four 
      years of implementation in Sierra Leone.
PG  - 145
LID - 10.1186/s12936-023-04575-6 [doi]
LID - 145
AB  - BACKGROUND: Intermittent Preventive Treatment of malaria in infants (IPTi) is a 
      malaria control strategy consisting of the administration of an anti-malarial 
      drug alongside routine immunizations. So far, this is being implemented 
      nationwide in Sierra Leone only. IPTi has been renamed as Perennial Malaria 
      Chemoprevention -PMC-, accounting for its recently recommended expansion into the 
      second year of life. Before starting a pilot implementation on PMC, the currently 
      implemented strategy and malaria prevalence were assessed in young children in 
      selected areas of Sierra Leone. METHODS: A cross-sectional, community-based, 
      multi-stage cluster household survey was conducted from November to December 2021 
      in selected districts of the Northern and northwestern provinces of Sierra Leone 
      among 10-23 months old children, whose caretakers gave written informed consent 
      to participate in the survey. Coverage of IPTi and malaria prevalence-assessed 
      with rapid diagnostic tests-were calculated using percentages and 95% confidence 
      intervals weighted for the sampling design and adjusted for non-response within 
      clusters. Factors associated with RDT + and iPTi coverage were also assessed. 
      RESULTS: A total of 720 children were recruited. Coverage of three IPTi doses was 
      50.57% (368/707; 95% CI 45.38-55.75), while prevalence of malaria infection was 
      28.19% (95% CI 24.81-31.84). Most children had received IPTi1 (80.26%, 574/707; 
      95% CI 75.30-84.44), and IPTi2 (80.09%, 577/707; 95% CI 76.30-83.40) and over 
      half of the children also received IPTi3 (57.72%, 420/707; 95% CI 53.20-62.11). 
      The uptake of each IPTi dose was lower than that of the vaccines administered at 
      the same timepoint at all contacts. CONCLUSION: In Sierra Leone, half of the 
      children received the three recommended doses of IPTi indicating an increase in 
      its uptake compared to previous data of just a third of children receiving the 
      intervention. However, efforts need to be made in improving IPTi coverage, 
      especially in the planned expansion of the strategy into the second year of life 
      following recent WHO guidelines.
CI  - (c) 2023. The Author(s).
FAU - Fombah, Augustin E
AU  - Fombah AE
AUID- ORCID: 0000-0002-2905-5414
AD  - Barcelona Institute for Global Health, Hospital Clinic-University of Barcelona, 
      Barcelona, Spain. augustin.fombah@isglobal.org.
AD  - Ministry of Health and Sanitation, Freetown, Sierra Leone. 
      augustin.fombah@isglobal.org.
FAU - Chen, Haily
AU  - Chen H
AD  - Barcelona Institute for Global Health, Hospital Clinic-University of Barcelona, 
      Barcelona, Spain.
FAU - Owusu-Kyei, Kwabena
AU  - Owusu-Kyei K
AD  - Barcelona Institute for Global Health, Hospital Clinic-University of Barcelona, 
      Barcelona, Spain.
FAU - Quinto, Llorenc
AU  - Quinto L
AD  - Barcelona Institute for Global Health, Hospital Clinic-University of Barcelona, 
      Barcelona, Spain.
AD  - Manhica Health Research Center, Manhica, Mozambique.
FAU - Gonzalez, Raquel
AU  - Gonzalez R
AD  - Barcelona Institute for Global Health, Hospital Clinic-University of Barcelona, 
      Barcelona, Spain.
AD  - Manhica Health Research Center, Manhica, Mozambique.
FAU - Williams, Julian
AU  - Williams J
AD  - College of Medicine and Allied Health Sciences, University of Sierra Leone, 
      Freetown, Sierra Leone.
FAU - Berne, Mireia LLach
AU  - Berne ML
AD  - Barcelona Institute for Global Health, Hospital Clinic-University of Barcelona, 
      Barcelona, Spain.
FAU - Wassenaar, Myrte
AU  - Wassenaar M
AD  - Barcelona Institute for Global Health, Hospital Clinic-University of Barcelona, 
      Barcelona, Spain.
AD  - University Medical Center Utrecht - Utrecht University, Utrecht, The Netherlands.
FAU - Jalloh, Abubakarr
AU  - Jalloh A
AD  - College of Medicine and Allied Health Sciences, University of Sierra Leone, 
      Freetown, Sierra Leone.
FAU - Sunders, Joe-Henry C
AU  - Sunders JC
AD  - College of Medicine and Allied Health Sciences, University of Sierra Leone, 
      Freetown, Sierra Leone.
FAU - Ramirez, Maximo
AU  - Ramirez M
AD  - Barcelona Institute for Global Health, Hospital Clinic-University of Barcelona, 
      Barcelona, Spain.
FAU - Bertran-Cobo, Cesc
AU  - Bertran-Cobo C
AD  - Barcelona Institute for Global Health, Hospital Clinic-University of Barcelona, 
      Barcelona, Spain.
FAU - Saute, Francisco
AU  - Saute F
AD  - Manhica Health Research Center, Manhica, Mozambique.
FAU - Ekouevi, Didier K
AU  - Ekouevi DK
AD  - Universite de Lome, Lome, Togo.
FAU - Briand, Valerie
AU  - Briand V
AD  - National Institute for Health and Medical Research (INSERM) UMR 1219, Research 
      Institute for Sustainable Development (IRD) EMR 271, Bordeaux Population Health 
      Centre, University of Bordeaux, Bordeaux, France.
FAU - Kamara, Anitta R Y
AU  - Kamara ARY
AD  - National Malaria Control Program, Directorate of Disease Prevention and Control, 
      Ministry of Health and Sanitation, Freetown, Sierra Leone.
FAU - Sesay, Tom
AU  - Sesay T
AD  - Directorate of Research and Training, Ministry of Health and Sanitation, 
      Freetown, Sierra Leone.
FAU - Samai, Mohamed
AU  - Samai M
AD  - College of Medicine and Allied Health Sciences, University of Sierra Leone, 
      Freetown, Sierra Leone.
AD  - Ministry of Health and Sanitation, Directorate Research and Training, Freetown, 
      Sierra Leone.
FAU - Menendez, Clara
AU  - Menendez C
AD  - Barcelona Institute for Global Health, Hospital Clinic-University of Barcelona, 
      Barcelona, Spain.
AD  - Manhica Health Research Center, Manhica, Mozambique.
LA  - eng
GR  - RIA 2020S/European and Developing Countries Clinical Trials Partnership/
PT  - Journal Article
DEP - 20230502
PL  - England
TA  - Malar J
JT  - Malaria journal
JID - 101139802
RN  - Z3614QOX8W (Pyrimethamine)
RN  - 88463U4SM5 (Sulfadoxine)
RN  - 0 (Drug Combinations)
SB  - IM
MH  - Child
MH  - Humans
MH  - Infant
MH  - Child, Preschool
MH  - *Pyrimethamine/therapeutic use
MH  - Sulfadoxine/therapeutic use
MH  - Cross-Sectional Studies
MH  - Sierra Leone
MH  - Drug Combinations
MH  - *Malaria/prevention & control
PMC - PMC10151216
OTO - NOTNLM
OT  - Child health
OT  - IPTi
OT  - Malaria prevention
OT  - PMC
OT  - Sierra Leone
OT  - Sub-Saharan Africa
COIS- The funder did not influence the contents of the outcome of this study. The 
      authors have no other affiliations or financial involvement with any organization 
      or entity with a financial interest in the subject matter or materials discussed 
      in this manuscript apart from what has been disclosed.
EDAT- 2023/05/02 00:42
MHDA- 2023/05/03 06:42
PMCR- 2023/05/02
CRDT- 2023/05/01 23:18
PHST- 2023/02/01 00:00 [received]
PHST- 2023/04/24 00:00 [accepted]
PHST- 2023/05/03 06:42 [medline]
PHST- 2023/05/02 00:42 [pubmed]
PHST- 2023/05/01 23:18 [entrez]
PHST- 2023/05/02 00:00 [pmc-release]
AID - 10.1186/s12936-023-04575-6 [pii]
AID - 4575 [pii]
AID - 10.1186/s12936-023-04575-6 [doi]
PST - epublish
SO  - Malar J. 2023 May 2;22(1):145. doi: 10.1186/s12936-023-04575-6.